Apoptosis induced by neoadjuvant chemotherapy in breast cancer

Pathology

Volumn 38, Issue 1, 2006, Pages 21-27

  Tiezzi, Daniel Guimarães ^a,b   De Andrade, Jurandyr Moreira ^a   Cândido Dos Reis, Francisco José ^a   Cosiski Marana, Heitor Ricardo ^a   Ribeiro Silva, Alfredo ^a   Tiezzi, Marcelo Guimarães ^c   Pereira, Antônio Plácido ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Department of Gynecology and Obstetrics   (Brazil)

^c Presidente Prudente Laboratory of Pathology and Cytopathology   (Brazil)

^d Departamento de Ginecologia e Obstetricia ^*

Author keywords

Apoptosis; Breast cancer; Immunohistochemical; Neoadjuvant chemotherapy; p53 protein

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; PROTEIN BCL 2; PROTEIN P53; TAXANE DERIVATIVE;

ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER TISSUE; CELL STRUCTURE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOPEROXIDASE STAINING; PROTEIN EXPRESSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 32944481032     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1080/00313020500465315     Document Type: Article

References (31)

1. Fisher ER, Wang J, Bryant J, et al. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95: 681-95.
2. Dieras V, Fumoleau P, Romieu G, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22: 4958-65.
3. Smith IE, Mainwaring PN. Primary chemotherapy. In: Bonadonna G, Hortobagyi GN, Gianni AM, editors. Textbook of Breast Cancer: A Clinical Guide to Therapy. London: Martin Dunitz. 1998; 104-5.
4. Faneyte IF, Schrama JG, Peterse JL, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003; 88: 406-12.
5. Symmans WF, Volm MD, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610-7.
6. Hayward JL, Carbone PP, Heusen JC, et al. Assessment of response to therapy in advanced breast cancer. Br J Cancer 1977; 114: 160-3.
7. Soini Y, Puhakka A, Kahlos K, et al. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1. Histopathology 2001; 39: 179-86.
8. Nagle RB, Fitzgibbons PL. Consensual interpretive guidelines for diagnostic immunohistochemistry. Am J Surg Pathol 2002; 26: 816-7.
9. Häcker G. The morphology of apoptosis. Cell Tissue Res 2000; 301: 5-7.
10. Cohen JJ. Apoptosis. Immunol Today 1993; 14: 126-30.
11. Meyn RE, Stephens LC, Ang KK, et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Biol 1993; 64: 583-91.
12. Wheeler JA, Stephens LC, Tornos C, et al. ASTRO Research Fellowship. Apoptosis as a predictor of tumor response to radiation in stage IB cervical carcinoma. American Society for Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys 1995; 32: 1487-93.
13. Cameron DA, Keen JC, Dixon JM, et al. Effective tamoxifen therapy of breast cancer involves both antiproliferative and pro-apoptotic changes. Eur J Cancer 2000; 36: 845-51.
14. Aihara M, Scardino PT, Truong LD, et al. The frequency of apoptosis correlates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995; 75: 522-9.
15. Carey LA, Metzger R, Dees EC, et al. American Joint Committee on Cancer Tumor-Node-Metastasis Stage After Neoadjuvant Chemotherapy and Breast Cancer Outcome. J Natl Cancer Inst 2005; 97: 1337-42.
16. Ellis PA, Smith IE, Mccarthy K, et al. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet 1997; 349: 849.
17. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995; 103: 300-7.
18. Paradiso A, Mangia A, Chiriatti A, et al. Biomarkers predictive for clinical efficacy of taxol-based chemotherapy in advanced breast cancer. Ann Oncol 2005; 16: 14-9.
19. Silvestrini R, Veneroni S, Daidone MG, Benini E, Borscchi P. The bcl-2 protein: a prognostic indicator strongly related top53 protein in lymph node-negative breast cancer in patients. J Natl Cancer Inst 1994; 86: 499-504.
20. Srivastava RK, Mi QS, Hardwick JM, et al. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Natl Acad Sci USA 1999; 96: 3775-80.
21. Leung LK, Wang TT. Differential effects of chemotherapeutic agents on the Bcl-2/Bax apoptosis pathway in human breast cancer cell line MCF-7. Breast Cancer Res Treat 1999; 55: 73-83.
22. Wang Q, Maloof P, Wang H, et al. Basic fibroblast growth factor downregulates Bcl-2 and promotes apoptosis in MCF-7 human breast cancer cells. Exp Cell Res 1998; 238: 177-87.
23. Ohmori T, Podack ER, Nishio K, et al. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993; 193: 30-6.
24. Bold RJ, Chandra J, McConkey DJ. Gencitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by bcl-2 content. Ann Surg Oncol 1999; 6: 279-85.
25. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 1995; 11: 1217-28.
26. Scatena CD, Stewart ZA, Mays D, et al. Mitotic phosphorylation of bcl-2 during normal cell cycle progression and taxol-induced growth arrest. J Biol Chem 1998; 273: 30777-84.
27. Erdem O, Dursun A, Coskun U, et al. The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori 2005; 91: 46-52.
28. Tsutsui S, Yasuda K, Higashi H, et al. Prognostic implication of p53 protein expression in relation to nuclear pleomorphism and the MIB-1 counts in breast cancer. Breast Cancer 2004; 11: 160-8.
29. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-55.
30. Bottini A, Berruti A, Bersiga A, et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients. Clin Cancer Res 2000; 6: 2751-8.
31. Brambilla E, Gazzeri S, Lantuejoul S, et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (bcl-2, bax and waf-1) in precursor bronchial lesions of lung cancer. Clin Cancer Res 1998; 4: 1609-18.